Prospective, randomized dose-ranging open phase II pilot study of quinupristin dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia

Two different doses of quinupristin/dalfopristin were compared with intrave nous vancomycin with regard to the efficacy and safety in the treatment of catheter-related staphylococcal bacteremia. A total of 39 patients were enr olled from 13 centers. For all treated patients with a baseline pathogen, o utcome was comparable for all antibiotic study regimens. Discontinuation of the antibiotic for an adverse clinical event occurred in 12% of patients r eceiving quinupristin/dalfopristin and in 15% of those receiving vancomycin . Quinupristin/dalfopristin may have the potential to serve as an alternati ve agent in the treatment of catheter-related staphylococcal bacteremia. Ho wever, larger prospective randomized trials are required.